Navigation Links
Astellas/GlaxoSmithKline's Vesicare Has Advantages Over Pfizer's Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
Date:4/3/2008

Superior Side-Effect Profile Earns Vesicare Gold Standard Status Over Sales-Leading Detrol LA/Detrusitol XL, According to a New Report from

Decision Resources

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on the reduction of urge urinary incontinence episodes (and the resulting improvement in a patient's quality of life) is the attribute that most influences urologists' prescribing decisions in the treatment of urge urinary incontinence. Clinical data and expert opinion show that Astellas/GlaxoSmithKline's Vesicare has advantages in this attribute over the market sales leader, Pfizer's Detrol LA/ Detrusitol XL.

The new report entitled Urge Urinary Incontinence: Commercial Windfall Awaits the Treatment That Offers Significant Improvement in Dryness Rates finds that a drug offering a greater reduction in the number of urge urinary incontinence episodes per week over Detrol LA/Detrusitol XL would earn a 25 percent patient share in this market. The report also finds that, although Detrol LA/Detrusitol XL is the sales leader in the urge urinary market, the current and future gold standard treatment for the indication is Vesicare.

At doses that provide superior efficacy, clinical data and expert opinion indicate that Vesicare is superior to Detrol LA/Detrusitol XL and its successor, Pfizer's Toviaz, in its side-effect profile -- particularly on rates of dry mouth, an important cause for discontinuation of therapy.

"We do not expect any therapy under development for urge urinary incontinence to displace Vesicare as the clinical gold standard treatment," said Cindy Mundy, Ph.D., principal director at Decision Resources. "While some therapies in development for this indication hold promise, most of them earned inferior scores in efficacy, safety and tolerabil
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Celebrity Introduces Students to Need, Advantages of Health Care Careers
2. Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes
3. Creative work has health advantages, Population Research Center study shows
4. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
5. New study shows promise in reducing surgical risks associated with surgical bleeding
6. Global Health Project targets reducing AIDS among Indias adolescents
7. Preventing or reducing enlarged heart decreases risk of heart failure
8. Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke
9. Safe Blood for Africa Foundations African Club 25 Greatly Reducing HIV Infections in African Youth
10. Breast cancer survivors optimistic, yet lack critical information on reducing recurrence
11. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Coast Dental and Orthodontics ... its newest practice, located at 1010 Shaw Avenue in ... general dentistry services , and specialty dental care including ... providing affordable and convenient dental care, our Clovis dentists ... . Call Coast Dental at 559-777-6113 to schedule an ...
(Date:9/30/2014)... More than 23 per cent of Canadians report being stressed ... the risk of poor mental and physical health, not everyone ... others especially those most likely to sweat the small ... new research from Concordia University has found a way to ... for healthcare professionals working to stop stress before it gets ...
(Date:9/30/2014)... 30, 2014 OZ Naturals announced ... brand on Amazon.com. , “The majority of our products ... categories on Amazon.com,” said Craig Romero, CEO of OZ Naturals, ... Amazon.co.uk and Canada on Amazon.ca , Romero went on to ... earlier last month, are already taking over top positions and ...
(Date:9/30/2014)... cannot multiply and cardiac muscles contain few stem ... after a heart attack. Now Tel Aviv University ... in cardiac tissue engineering. , Dr. Tal Dvir ... Department of Biotechnology, Department of Materials Science and ... been developing sophisticated micro- and nanotechnological tools ...
(Date:9/30/2014)... 30th, 2014 A new report launched today ... Irish Longitudinal Study on Ageing) conducted by academics ... College Dublin, Ireland, has highlighted the serious, complex ... intellectual disability population. , The IDS-TILDA study is ... and the only one in the world with ...
Breaking Medicine News(10 mins):Health News:Coast Dental Clovis Celebrates Grand Opening 2Health News:Coast Dental Clovis Celebrates Grand Opening 3Health News:How to predict who will suffer the most from stress 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4
... , AMSTERDAM and SAN DIEGO, July 15 ... that it has reached an agreement to acquire the assets of ... which involves the management of a patient,s body temperature. InnerCool, a ... ), will be acquired in an asset purchase transaction for US ...
... WESTFORD, Mass., July 15 Cynosure, Inc. ... manufacturer of a broad array of light-based aesthetic treatment systems, today ... on Tuesday, July 28, 2009 at 9:00 a.m. ET. , ... Executive Officer Michael Davin and Executive Vice President and Chief Financial ...
... , MORRISTOWN, N.J., July 15 ... specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, ... with the U.S. Food and Drug Administration seeking approval to ... the expiration of a patent owned by Supernus Pharmaceuticals, Inc. ...
... , , NASHVILLE, Tenn. and ... find that surveyed pharmacy directors of both national and single ... a medical benefit to a pharmacy benefit by 2014, citing ... will be most affected by this shift. According to the ...
... 15 While politicians spend countless hours bickering over how to ... aisle may be ignoring important research into this very subject, some ... Obama,s health care proposal contains flaws that will not only cost ... health care. , , ...
... , , SAN DIEGO, July ... announced today that its New Drug Application (NDA) for Acetavance(TM) (intravenous ... and fever in adults and children, has been accepted for filing ... Priority Review. Priority Review is granted to those products that address ...
Cached Medicine News:Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 2Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 3Health News:Cynosure To Announce Second-Quarter 2009 Financial Results On July 28 2Health News:Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R) 2Health News:Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 2Health News:Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 3Health News:Will Government Health Care Make Us Sick? Health Expert Suggests 5 Shocking Flaws of Obamacare 2Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 2Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 3Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 4
(Date:9/30/2014)... New York , September 30, 2014 ... - Global Industry Analysis, Market Size, Share, Growth and ... is expected to be worth USD 20.8 billion in ... billion in 2017, growing at a CAGR of 7.3% ... fundamental elements needed for various health purposes, especially to ...
(Date:9/30/2014)... DIEGO , 30. September 2014 ... - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- und ... Ursachen entwickelt, die zu komplexen Herzrhythmusstörungen ... hat den Abschluss einer zusätzlichen Finanzierung ...
(Date:9/30/2014)... ST. PAUL, Minn. , Sept. 30, 2014 /PRNewswire/ ... the United States abused prescription pain ... dependence include detoxification or maintenance treatment, which entails the ... and costs of these treatments are important when developing ... studies by pharmacy benefit manager Prime Therapeutics ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... Mylan Inc. (Nasdaq: MYL ) today announced ... the company,s 6.50% Mandatory Convertible Preferred Stock (the "Preferred ... As previously announced, each share converted into 58.5480 shares ... the Articles of Incorporation, reflecting strong stock performance since ...
... YORK, Nov. 15, 2010 Reportlinker.com announces that ... its catalogue: Global Ophthalmic Instrumentation ... This report analyzes the worldwide markets ... US$ Million by the following segments: Diagnostic Devices ...
Cached Medicine Technology:Reportlinker Adds Global Ophthalmic Instrumentation Industry 2Reportlinker Adds Global Ophthalmic Instrumentation Industry 3Reportlinker Adds Global Ophthalmic Instrumentation Industry 4Reportlinker Adds Global Ophthalmic Instrumentation Industry 5Reportlinker Adds Global Ophthalmic Instrumentation Industry 6Reportlinker Adds Global Ophthalmic Instrumentation Industry 7Reportlinker Adds Global Ophthalmic Instrumentation Industry 8Reportlinker Adds Global Ophthalmic Instrumentation Industry 9Reportlinker Adds Global Ophthalmic Instrumentation Industry 10Reportlinker Adds Global Ophthalmic Instrumentation Industry 11Reportlinker Adds Global Ophthalmic Instrumentation Industry 12Reportlinker Adds Global Ophthalmic Instrumentation Industry 13Reportlinker Adds Global Ophthalmic Instrumentation Industry 14Reportlinker Adds Global Ophthalmic Instrumentation Industry 15Reportlinker Adds Global Ophthalmic Instrumentation Industry 16Reportlinker Adds Global Ophthalmic Instrumentation Industry 17Reportlinker Adds Global Ophthalmic Instrumentation Industry 18Reportlinker Adds Global Ophthalmic Instrumentation Industry 19Reportlinker Adds Global Ophthalmic Instrumentation Industry 20Reportlinker Adds Global Ophthalmic Instrumentation Industry 21Reportlinker Adds Global Ophthalmic Instrumentation Industry 22Reportlinker Adds Global Ophthalmic Instrumentation Industry 23Reportlinker Adds Global Ophthalmic Instrumentation Industry 24Reportlinker Adds Global Ophthalmic Instrumentation Industry 25
... are a convenient, reusable, patient-friendly and ... common orthopedic conditions/instabilities. These products are ... and lateral to medial influence of ... skin and soft tissue structures. Maximum ...
... The C.Ti.2 Hockey is a lightweight, ... meet the unique requirements of hockey,players. Tested ... a new, streamlined frame shape that is ... (VMO). Plus, the upper and lower lateral ...
... Drytex Adjustable Patella Donut is a ... nylon core and polyester Lycra Fabric ... trimable full-circumference donut provides for patellar ... neoprene based allergies or irritations. Click ...
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
Medicine Products: